Study Sponsor:
Alexion Pharmaceuticals, Inc.
Full IRB Study Title:
ALXN1210-TMA-314: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)
If you are interested in this study or have questions about your child's eligibility, please contact:
Showers Family Center for Childhood Cancer and Blood Disorders. 330-543-8730